CA2439530C - Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases - Google Patents

Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases Download PDF

Info

Publication number
CA2439530C
CA2439530C CA2439530A CA2439530A CA2439530C CA 2439530 C CA2439530 C CA 2439530C CA 2439530 A CA2439530 A CA 2439530A CA 2439530 A CA2439530 A CA 2439530A CA 2439530 C CA2439530 C CA 2439530C
Authority
CA
Canada
Prior art keywords
hmgb1
cells
fragment
antibody
box
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2439530A
Other languages
English (en)
French (fr)
Other versions
CA2439530A1 (en
Inventor
Tiziana Bonaldi
Paola Scaffidi
Susanne Mueller
Bernard Degryse
Marco E. Bianchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio3 Research Srl
Original Assignee
Bio3 Research Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Research Srl filed Critical Bio3 Research Srl
Publication of CA2439530A1 publication Critical patent/CA2439530A1/en
Application granted granted Critical
Publication of CA2439530C publication Critical patent/CA2439530C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2439530A 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases Expired - Fee Related CA2439530C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ITMI2001A000562 2001-03-16
PCT/IT2002/000153 WO2002074337A1 (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
CA2439530A1 CA2439530A1 (en) 2002-09-26
CA2439530C true CA2439530C (en) 2016-11-08

Family

ID=11447291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2439530A Expired - Fee Related CA2439530C (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Country Status (14)

Country Link
US (4) US7754217B2 (enExample)
EP (1) EP1368060B1 (enExample)
JP (1) JP4822654B2 (enExample)
CN (2) CN1537014B (enExample)
AT (1) ATE468137T1 (enExample)
AU (1) AU2002247977C1 (enExample)
CA (1) CA2439530C (enExample)
DE (1) DE60236413D1 (enExample)
DK (1) DK1368060T3 (enExample)
ES (1) ES2346408T3 (enExample)
IT (1) ITMI20010562A1 (enExample)
MX (1) MXPA03008364A (enExample)
PT (1) PT1368060E (enExample)
WO (1) WO2002074337A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
BR0209689A (pt) * 2001-05-15 2006-02-07 Long Island Jewish Res Inst Uso de fragmento de hmg como agente anti-inflamatório
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
DE60326453D1 (de) 2002-07-03 2009-04-16 Ct Cardiologico Monzino S P A Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
EP1579221A2 (de) * 2003-01-03 2005-09-28 Alcedo Biotech GmbH Verwendungen von hmgb, hmgn, hmga proteinen
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
PT1768677E (pt) * 2004-07-02 2008-10-06 Creabilis Therapeutics Spa Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1
US20090062187A1 (en) 2004-07-20 2009-03-05 Marco Bianchi Use of Hmgb1 for Wound Healing
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CA2579094C (en) 2004-09-03 2014-12-02 Creabilis Therapeutics S.P.A. Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
JP2008520552A (ja) 2004-10-22 2008-06-19 メディミューン，インコーポレーテッド Ｈｍｇｂ１に対する高親和性の抗体およびその使用法
ITRM20050032A1 (it) * 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
KR101379693B1 (ko) 2005-08-25 2014-04-10 크리어빌리스 쎄라퓨틱스 에스.피.에이. Ｋ-252ａ 및 그의 유도체의 중합체 컨쥬게이트
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
JP2010503630A (ja) 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
US8470325B2 (en) 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
WO2011007876A1 (ja) 2009-07-16 2011-01-20 Ｎｅｃソフト株式会社 Ｈｍｇｂ１結合核酸分子およびその用途
JP5467313B2 (ja) 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
EP2632446B1 (en) 2010-10-30 2018-12-12 Oxford University Innovation Limited Treatment for dupuytren's disease
EP3358011B1 (en) 2011-04-26 2020-03-04 StemRIM Inc. Peptide for inducing regeneration of tissue and use thereof
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
JP6253589B2 (ja) 2012-10-25 2017-12-27 株式会社ジェノミックス Ｈｍｇｂ１断片を利用した新規心筋梗塞の治療法
DK2913059T3 (en) 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
MX2015009547A (es) 2013-01-28 2015-11-25 Evec Inc Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo.
IL242807A0 (en) 2015-11-26 2016-04-21 Novamed Ltd Test facility
EP3386529A2 (en) 2015-12-11 2018-10-17 Ruprecht-Karls-Universität Heidelberg Combined preparations of pkm2 modulators and hmgb1
AU2018213671B2 (en) 2017-01-27 2024-06-06 Osaka University Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
AU2018376452A1 (en) 2017-12-01 2020-06-25 Osaka University Ectodermal mesenchymal stem cells and method for producing same
EP3718561A4 (en) 2017-12-01 2021-07-21 Stemrim Inc. Therapy for inflammatory bowel disease
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
WO2021242180A1 (en) * 2020-04-22 2021-12-02 Chulalongkorn University A composition and a method of rejuvenating dna and preventing dna damage

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6398808B1 (en) 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
BR0209689A (pt) * 2001-05-15 2006-02-07 Long Island Jewish Res Inst Uso de fragmento de hmg como agente anti-inflamatório
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
US20090062187A1 (en) * 2004-07-20 2009-03-05 Marco Bianchi Use of Hmgb1 for Wound Healing
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof

Also Published As

Publication number Publication date
US7754217B2 (en) 2010-07-13
JP4822654B2 (ja) 2011-11-24
CN101773669A (zh) 2010-07-14
US20100172896A1 (en) 2010-07-08
ATE468137T1 (de) 2010-06-15
DE60236413D1 (de) 2010-07-01
US20040136979A1 (en) 2004-07-15
ES2346408T3 (es) 2010-10-15
MXPA03008364A (es) 2004-11-12
AU2002247977A2 (en) 2004-02-26
CN1537014B (zh) 2012-04-25
WO2002074337A1 (en) 2002-09-26
US20080171052A1 (en) 2008-07-17
EP1368060B1 (en) 2010-05-19
AU2002247977B2 (en) 2006-12-14
AU2002247977C1 (en) 2008-09-18
WO2002074337A8 (en) 2003-08-28
PT1368060E (pt) 2010-08-24
AU2002247977B8 (en) 2007-03-15
US20100297107A1 (en) 2010-11-25
ITMI20010562A1 (it) 2002-09-16
CA2439530A1 (en) 2002-09-26
DK1368060T3 (da) 2010-08-30
US8058239B2 (en) 2011-11-15
CN1537014A (zh) 2004-10-13
EP1368060A1 (en) 2003-12-10
JP2004523579A (ja) 2004-08-05
HK1069316A1 (en) 2005-05-20
AU2002247977A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
US7754217B2 (en) HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
Degryse et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells
Prater et al. The properdin-like type I repeats of human thrombospondin contain a cell attachment site.
Clauss et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.
JPH01135724A (ja) 非特異的炎症の治療法
Chen et al. Interleukin-17 induces angiogenesis in human choroidal endothelial cells in vitro
US9353189B2 (en) Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
Ambort et al. Specific processing of tenascin-C by the metalloprotease meprinβ neutralizes its inhibition of cell spreading
EP1817327A1 (en) Antigenic epitopes of interleukin-21, related antibodies and their use in medical field
US20090170751A1 (en) Formation of superfibronectin by BBK32 and uses therefor
Kitamura et al. Endothelin-1 is a potent stimulator of α1β1 integrin-mediated collagen matrix remodeling by rat mesangial cells
JP2006516024A (ja) α１β１インテグリンの誘導性リガンドおよび使用
JP5341505B2 (ja) 抗体及びその使用
HK1146703A (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HK1069316B (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
US20080118502A1 (en) Tissue Repair By Modulation Of Beta-1 Integrin Biological Function
Neves-Ferreira et al. New methodology for the obtainment of antibothropic factors from the South American opossum (Didelphis marsupialis) and jararaca snake (Bothrops jararaca).
ES2362655T3 (es) Métodos y composiciones para suprimir la diferenciación de fibrocitos.
Macleod IL-36 member activation and secretion, and their role in immune defence
Khunkaewla Doktorln der Medizinischen Wissenschaft
JPH08511941A (ja) ヒト細胞接着性タンパク質ａａｍｐ‐１及びその利用

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190312